BCTX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2026Q2

FY2026Q3

-3.280

-90.06%

-4.840

-79.23%

-2.740

-83.29%

Estimates Revision

The market is revising No Change the revenue expectations for BriaCell Therapeutics Corp. (BCTX) for FY2026, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 9.32%.

Revenue Estimates for FY2026

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2026

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+9.32%

In Past 3 Month

1 Analyst Rating

Wall Street analysts forecast BCTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BCTX is 39.90 USD with a low forecast of 39.90 USD and a high forecast of 39.90 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 8.975

Low

39.90

Averages

39.90

High

39.90

Current: 8.975

Low

39.90

Averages

39.90

High

39.90

HC Wainwright & Co.

Emily Bodnar

Strong Buy

Reiterates

$32

2025-04-22

Reason

HC Wainwright & Co.

Emily Bodnar

Price Target

$32

2025-04-22

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Emily Bodnar

Strong Buy

Maintains

$15 → $32

2025-02-03

Reason

HC Wainwright & Co.

Emily Bodnar

Price Target

$15 → $32

2025-02-03

Maintains

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for Briacell Therapeutics Corp (BCTX.O) is -0.78, compared to its 5-year average forward P/E of -3.29. For a more detailed relative valuation and DCF analysis to assess Briacell Therapeutics Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.29

Current PE

-0.78

Overvalued PE

-0.45

Undervalued PE

-6.13

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.68

Current PS

0.00

Overvalued PS

3.03

Undervalued PS

-1.66

Financials

Annual

Quarterly

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

BCTX News & Events

Events Timeline

No data

News

3.5

11-25Newsfilter

BriaCell Presents Positive Clinical Data Across Three Studies at SABCS 2025

9.0

11-18Newsfilter

BriaCell Chosen to Showcase Phase 2 and 3 Clinical Findings at SABCS® 2025

9.0

11-07Newsfilter

BriaCell Showcases Strong Anti-Cancer Effects of Bria-OTS+™ at SITC 2025

People Also Watch

Frequently Asked Questions

What is Briacell Therapeutics Corp (BCTX) stock price today?

The current price of BCTX is 8.975 USD — it has decreased -5.92 % in the last trading day.

What is Briacell Therapeutics Corp (BCTX)'s business?

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.

What is the price predicton of BCTX Stock?

What is Briacell Therapeutics Corp (BCTX)'s revenue for the last quarter?

Briacell Therapeutics Corp revenue for the last quarter amounts to -8.32M USD, increased 61.52 % YoY.

What is Briacell Therapeutics Corp (BCTX)'s earnings per share (EPS) for the last quarter?

Briacell Therapeutics Corp. EPS for the last quarter amounts to -7704796.00 USD, increased 10.78 % YoY.

What changes have occurred in the market's expectations for Briacell Therapeutics Corp (BCTX)'s fundamentals?

How many employees does Briacell Therapeutics Corp (BCTX). have?

Briacell Therapeutics Corp (BCTX) has 22 emplpoyees as of December 16 2025.

What is Briacell Therapeutics Corp (BCTX) market cap?

Today BCTX has the market capitalization of 16.91M USD.